Background Epicardial adipose tissue (EAT) plays an important role in cardiometabolic risk.
EAT is a modifiable risk factor and could be a potential therapeutic target for drugs that …

Epicardial adipose tissue (EAT) and pericardial adipose tissue (PAT) are metabolically
active fat depots implicated in cardiovascular disease, and EAT has potential as a novel …

Epicardial adipose tissue (EAT) is located between the heart muscle and visceral
pericardium, where it has direct contact with coronary blood vessels. Elevated thickness of …

Epicardial adipose tissue (EAT) is located between the myocardium and visceral
pericardium. The unique anatomy and physiology of the EAT determines its great potential …

(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and
cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial …

Epicardial adipose tissue is defined as a deposit of adipocytes with pathophysiological
properties similar to those of visceral fat, located in the space between the myocardial …

Background and aims Glucagon-like peptide-1 (GLP-1) analogues reduce body fat and
cardiovascular events in patients with type 2 diabetes. Accumulation of epicardial adipose …

Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Introduction Imbalance between pro-and anti-inflammatory cytokines secreted from visceral
adipose tissue (VAT) contributes to the pathogenesis of certain cardiovascular and …

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with
various comorbidities, multiple cardiac and extracardiac pathophysiologic abnormalities …